Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

3.20
+0.04001.27%
Post-market: 3.17-0.0300-0.94%19:39 EDT
Volume:42.63K
Turnover:141.95K
Market Cap:5.22M
PE:-0.17
High:3.47
Open:3.24
Low:3.16
Close:3.16
52wk High:71.50
52wk Low:3.04
Shares:1.63M
Float Shares:1.20M
Volume Ratio:1.68
T/O Rate:3.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:1.63
PE(LYR):-0.06

Loading ...

Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101

TIPRANKS
·
Yesterday

Ernexa Targets Q4 2026 IND Filing for First-in-Human ERNA-101 Trial in Platinum-Resistant Ovarian Cancer

Reuters
·
Yesterday

Ernexa Therapeutics - no Teratoma Formation Observed in Erna-101-Treated Animals Through Six-Month Tumorigenicity Phase

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics Reports Compelling Erna-101 Safety Results Across Three Critical Ind-Enabling Studies, Advancing Toward Planned Q4 2026 Ind

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics - Biodistribution Study Shows no Significant Erna-101 Signal in Tumor-Free Animals or Non-Tumor Tissues

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics - Repeat-Dose Glp Toxicology Study Shows no Erna-101-Related Adverse Findings

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

GlobeNewswire
·
Yesterday

Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting

TIPRANKS
·
Sep 29

Ernexa Therapeutics CEO to Present at Cell & Gene Meeting on the Mesa Emerging Track

Reuters
·
Sep 29

Ernexa Therapeutics Director Robert J. Spiegel Files Initial Beneficial Ownership Statement

Reuters
·
Sep 23

Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors

Reuters
·
Sep 17

Ernexa Therapeutics - Intends to Broaden Oncology Program and Advance Next-Generation Imsc Candidates

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - to Concentrate Near-Term Resources on Erna-101 and Broaden Oncology Strategy

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics Reports Positive Disease Modifying Erna-201 Preclinical Data, Reinforcing Imsc Platform as Company Accelerates Oncology Strategy and Erna-101 Toward First-in-Human Dosing

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - to Advance Erna-101 Toward Ind Submission for Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - Clinical Data from Erna-101 Proc Study Expected in Q4 2027

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - Pauses Additional Preclinical Development Expenditures on Erna-201

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing

GlobeNewswire
·
Sep 15

Ernexa Therapeutics CEO Sanjeev Luther Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 14

Ernexa Therapeutics Director David Polinsky Files Initial Beneficial Ownership Statement

Reuters
·
Aug 28